Onset: 30–60 minutes for capsules/tablets on empty stomach. Tinctures (alcoholic extracts) faster, ~15-30 min. Tea infusions slower and weaker due to limited valerenic-acid solubility in water.

Peak: ~1.5-2.5 hours after dose. Subjective effect is mild — "slight warmth, easier to put the phone down, marginal reduction in racing thoughts." Far below benzodiazepine sedation.

Plateau: 3-5 hours. Cumulative effects with consistent multi-week dosing — single-night use is generally underwhelming; week-2 onwards is when chronic users say they notice it.

Taper: 4-8 hours total effect. R-stereochemistry of valerenic acid has a half-life around 1.1 hours but the lipophilic sesquiterpenes redistribute slowly.

Characteristic effects:

• Mild myorelaxation; not the leaden-limbs feeling of phenibut or alcohol
• Subtle anxiolysis; harder to detect on a single trial than chronically
• Light, sometimes vivid dreams (community data shows 5 "vivid-dreams" mentions)
• The smell-and-taste problem — capsules don't fully hide a faint sock-locker burp. Tinctures are worse. Tea is acrid.
• Some users describe a "watching the room get quieter" feeling for 30 minutes before sleep — placebo-confounded but consistent
• ~10% of users get paradoxical alerting/agitation instead of sedation — the "valerian paradox"

Honest variability: Two users taking the same brand at the same dose can have wildly different experiences. The bioactive variability across batches (valerenic acid content 0.1-1.5% in commercial products labeled "0.8%") is part of this. Combine that with placebo response and inherent valepotriate instability and you have one of the more variable botanicals on the market.

• Tolerance buildup: Not formally studied with kinetics. Forum reports of "stops working at week 6-12" are common but might confound with novelty/expectancy regression.
• Mechanism for tolerance: Plausibly GABA-A β3 receptor downregulation with chronic exposure, mirroring the well-characterized pattern for benzodiazepines (though much weaker because valerian is a weaker agonist).
• Cycling protocols: Not strictly required for safety, but if using daily for sleep, consider 1-2 week off cycles every 8-12 weeks to test whether the underlying sleep problem still exists.
• Discontinuation: Generally smooth. Theoretical rebound insomnia for 1-3 nights at high-dose discontinuation. The Garges 1998 case is the outlier, not the norm.

Synergistic with

• Hops (Humulus lupulus, 60-120 mg) — better RCT support as combo than monotherapy. Ze 91019 product is the canonical formulation; works on similar GABA-A pathway.
• Lemon balm (Melissa officinalis, 240 mg) — anxiety + sleep combo. Adds mild serotonergic + acetylcholine modulation.
• Magnesium glycinate (200-400 mg) — additive GABAergic + NMDA antagonist relaxation. The single best mineral co-stack for sleep.
• L-theanine (200 mg) — alpha-wave promotion + glutamate modulation. Smooths anxiety dimension.
• Apigenin (50 mg) — another GABA-A PAM. Similar mechanism, modest dose-additive sedation.
• Glycine (3 g) — separate mechanism (NMDA glycine site, body-temp drop). Stacks cleanly.

Avoid stacking with

• Benzodiazepines — Additive GABAergic depression; theoretical respiratory risk at high combined doses. Clinical interaction reports exist.
• Z-drugs (zolpidem, eszopiclone, zaleplon) — Same logic. Skip.
• Phenibut — Same logic plus much stronger CNS depression; combined effect = oversedation, motor impairment.
• Alcohol — Additive sedation; multiple case reports of profound somnolence.
• Opioids — Additive respiratory depression risk at high doses.
• Sedating antihistamines (diphenhydramine, doxylamine) — Additive sedation + anticholinergic load.
• Barbiturates — Strongly additive; avoid.
• Other strong GABAergics (kava, kratom, gabapentin/pregabalin) — Caution; significant additive sedation reported.

Neutral / safe co-administration

• All routine V4 supplements (Mg, NAC, citicoline, PS, DHA, curcumin, rhodiola, theanine, glycine, D3/K2, beta-alanine, vitamin C) — no interactions known.
• Creatine — neutral.
• Standard SSRIs/SNRIs — neutral; one small case of valerian-fluoxetine drowsiness but generally fine.
• Most peptides (Semax, Selank, BPC-157, TB-500) — neutral.

Valerian's metabolic profile:

• Valerenic acid is primarily metabolized via hepatic glucuronidation and minor CYP3A4 oxidation.
• In vitro evidence of CYP3A4 inhibition exists but is generally not clinically meaningful at OTC doses.
• Valepotriates are unstable and metabolized rapidly; product variability dominates pharmacology variability.

Clinically relevant interactions:

1. CNS depressants — additive sedation

• Benzodiazepines, Z-drugs, opioids, sedating antihistamines, alcohol, barbiturates, GHB, phenibut, kava. Risk increases with concentrated extracts. Avoid stacking, especially with alcohol.

2. Anesthesia interactions

• Case reports of prolonged sedation post-anesthesia with chronic high-dose valerian. Hold ≥2 weeks before elective surgery.

3. CYP3A4 substrates — possibly mildly elevated levels

• Rarely clinically relevant. Caveat for narrow-therapeutic-index drugs (e.g., cyclosporine, certain anti-arrhythmics) where any inhibition matters.

4. Hepatically-cleared drugs

• Avoid co-use with other potentially hepatotoxic agents (acetaminophen, statins at high dose, isoniazid). Watch LFTs.

5. Levodopa

• Theoretical mild interaction via GABAergic modulation — not clinically established.

6. Iron absorption

• Tannins in whole-root preparations can reduce non-heme iron absorption when co-administered with meals. Take iron separately by ≥2 hours.

Little established. Valerian's primary metabolism is glucuronidation rather than CYP, so most pharmacogenomic effects are blunted. CYP3A4 expressers might clear minor metabolites faster but the clinical relevance is minimal. COMT and HTR2A variants might explain subjective non-responders but no validated marker exists. UGT polymorphisms (relevant for glucuronidation) have not been studied for valerian.

For Dylan: 23andMe results (June 2026) will provide CYP3A4/5 + UGT data but no actionable valerian-specific guidance is available. The pharmacogenomics here is much less important than for modafinil or SSRIs.

Quality red flags:

• "Valerian root powder" with no standardization — bioactive content unknown.
• Combination products with vague proprietary blends — dose not verifiable.
• Cheapest bulk-bin products — likely older, valepotriate-degraded stock.

Best evidence-based product: Ze 91019 (valerian-hops) for sleep-onset insomnia. For monotherapy: NOW Foods Valerian Root Extract 500mg or Nature's Way Valerian Standardized Extract 250mg. Pure Encapsulations is high-quality but premium-priced.

For Dylan specifically: Not recommended. If experimenting, choose Ze 91019 or NOW Foods 500mg extract; 4-week trial only; track sleep onset, sleep efficiency (Oura), morning grogginess, mood. Expect modest signal at best.

Baseline (before starting)

• Subjective sleep VAS (1-10) for 7-14 nights
• Sleep diary: sleep-onset latency, # awakenings, total sleep time
• PSQI (Pittsburgh Sleep Quality Index) — single-page validated questionnaire; pre/post comparison
• Oura/Whoop ring data if available: sleep efficiency, REM%, deep%, average HR overnight
• ALT/AST baseline (covered in June 2026 bloodwork for Dylan)
• Anxiety baseline (GAD-7 or simple VAS)

During use

• Daily: sleep diary — onset latency, awakenings, morning mood (1-10 VAS), grogginess (1-10 VAS)
• Weekly: subjective sleep quality VAS — average over 7 nights
• Week 4: ring-based sleep architecture — REM and deep sleep should not be substantially worse than baseline
• Week 4 and 12: PSQI — track over time
• Monthly: side-effect check-in — vivid dreams, morning grogginess, paradoxical effects

Red-flag stop criteria

• Any new rash or skin reaction → stop
• New jaundice, dark urine, fatigue out of proportion → check LFTs immediately
• Worsening sleep over 4-week trial (paradoxical effect) → discontinue
• Any new neurological symptom (tremor, ataxia) → stop and consult
• Morning grogginess that interferes with training/work for >5 days → reduce dose or stop

Post-cycle (if cycled)

• 1-week off period: do you feel notably worse than during use? Calibrates real benefit vs expectancy.
• Sleep architecture: should normalize within 1-3 nights off.